+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05211401

Study of Rituximab 1000 mg Versus Placebo to Improve Heart Function After ST-Elevation Myocardial Infarction STEMI

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-08-12

372

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how a single injection of rituximab affects heart function after an acute anterior ST-elevation myocardial infarction STEMI. This European phase IIb trial compares a 1000 mg dose of rituximab to a placebo, focusing on left ventricular systolic function measured by cardiac magnetic resonance imaging CMR at 6 months. The study aims to understand the impact of B cell depletion on heart remodeling and dysfunction following a heart attack. Participants will receive either a single infusion of 1000 mg rituximab or a placebo within 3 hours after primary percutaneous coronary intervention PPCI. The study involves random assignment to one of these two groups. Blood samples for biomarkers related to immune response and inflammation will be collected at admission, discharge, and 6 months. Continuous cardiac telemetry and ECG measurements will monitor patients during and after infusion. CMR scans will assess heart function and damage at 5 days and 6 months post-treatment. Throughout the study, participants will undergo blood tests for kidney function, hematologic parameters, and NT-pro-BNP at specified timepoints. Follow-up contacts by phone or hospital visits will occur at 30 days, 3 months, and 12 months after randomization. The primary outcome is left ventricular ejection fraction at 6 months, with additional measures including infarct size, edema, microvascular obstruction, and treatment-related adverse events. Participant involvement lasts through the 12-month follow-up period.

CONDITIONS

Brief Title

Rituximab in Patients With ST-elevation Myocardial Infarction

Research Team

G

Gabriel STEG

Z

Ziad MALLAT

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here